Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fourth-dose COVID-19 booster trial in adults previously vaccinated with CoronaVac and a third-dose booster
ISRCTN12022293Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tozinameran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Oxford. Primary endpoints: Anti-Spike IgG antibody titers, Anti-Spike IgG antibody titers after fourth dose and 1 more. Started Jul 2022; status: completed.
02
Drugs
tozinameranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN12022293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12022293.